Padcev (enfortumab vedotin) Letter of Medical Necessity
Padcev (enfortumab vedotin) is a Nectin-4–targeting ADC that has transformed the treatment of metastatic urothelial cancer. In combination with pembrolizumab, it demonstrated unprecedented OS and PFS as first-line therapy and is now a Category 1 NCCN recommendation. PA requires careful documentation of prior therapy history, histology confirmation, and cisplatin eligibility for the first-line combination indication.
FDA-Approved Indications
- ● locally advanced or metastatic urothelial cancer (mUC) — monotherapy in platinum/checkpoint inhibitor–relapsed patients
- ● mUC first-line in combination with pembrolizumab (Keytruda) in cisplatin-ineligible or unselected patients
Why Padcev Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Prior therapy lines not documented (monotherapy indication requires prior platinum and prior PD-1/PD-L1 therapy)
- 2. Histology not confirmed as urothelial carcinoma (transitional cell carcinoma of bladder, ureter, urethra, or renal pelvis)
- 3. Combination indication: pembrolizumab eligibility and PDL1 status not addressed
- 4. Cisplatin eligibility status not documented for first-line combination use
- 5. ECOG performance status not provided
- 6. Peripheral neuropathy baseline assessment missing (neuropathy risk with MMAE payloads)
- 7. Hyperglycemia history not addressed (risk of severe cutaneous reactions with uncontrolled diabetes)
What to Include in a Padcev Letter of Medical Necessity
Document urothelial carcinoma histology (pathology report with primary site), clinical disease stage (locally advanced or metastatic), and the applicable indication. For monotherapy (relapsed): prior platinum-containing chemotherapy and prior anti-PD-1/PD-L1 therapy with progression dates. For first-line combination with pembrolizumab: cisplatin eligibility assessment (CrCl, ECOG PS, neuropathy, hearing loss — if ineligible, document specific reason), PDL1 expression status (CPS ≥10 preferred but not required per FDA label), ECOG PS 0-1, and absence of uncontrolled hyperglycemia or severe neuropathy.
Key clinical evidence to cite:
- ✓ EV-301 Phase 3 — OS 12.9 vs 8.9 months in platinum/checkpoint inhibitor–relapsed mUC (HR 0.70)
- ✓ EV-302/KEYNOTE-869 Phase 3 — EV + pembrolizumab vs gemcitabine/platinum: PFS HR 0.45, OS HR 0.47 (first-line)
- ✓ Converted from accelerated to full approval based on EV-301 and EV-302 data
- ✓ First ADC approved in bladder/urothelial cancer
Relevant guidelines:
- 📖 NCCN Bladder Cancer Guidelines (Category 1 for relapsed mUC and first-line combination)
- 📖 EAU Urothelial Carcinoma Guidelines
- 📖 ASCO Urothelial Cancer Guidelines
Padcev Prior Authorization Criteria
Standard criteria across major US payers for Padcev. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Prior therapy lines not documented (monotherapy indication requires prior platinum and prior PD-1/PD-L1 therapy)
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Padcev
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Padcev Prior Authorization FAQ
Why was my Padcev prior authorization denied?
The most common denial reasons for Padcev are: Prior therapy lines not documented (monotherapy indication requires prior platinum and prior PD-1/PD-L1 therapy); Histology not confirmed as urothelial carcinoma (transitional cell carcinoma of bladder, ureter, urethra, or renal pelvis); Combination indication: pembrolizumab eligibility and PDL1 status not addressed; Cisplatin eligibility status not documented for first-line combination use; ECOG performance status not provided; Peripheral neuropathy baseline assessment missing (neuropathy risk with MMAE payloads); Hyperglycemia history not addressed (risk of severe cutaneous reactions with uncontrolled diabetes).
What should a Padcev Letter of Medical Necessity include?
Document urothelial carcinoma histology (pathology report with primary site), clinical disease stage (locally advanced or metastatic), and the applicable indication. For monotherapy (relapsed): prior platinum-containing chemotherapy and prior anti-PD-1/PD-L1 therapy with progression dates. For first-line combination with pembrolizumab: cisplatin eligibility assessment (CrCl, ECOG PS, neuropathy, hearing loss — if ineligible, document specific reason), PDL1 expression status (CPS ≥10 preferred but not required per FDA label), ECOG PS 0-1, and absence of uncontrolled hyperglycemia or severe neuropathy.
Which payers cover Padcev?
Padcev is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Medicare Part B, though formulary tier and prior authorization criteria vary.